Abstract
We report the case of a patient who died from the rare complication of Listeriosis in the immediate phase following alemtuzumab administration one month after discontinuing dimethyl fumarate (DMF). There is considerable overlap with typical post-infusion symptoms therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic therapy is advocated.
Original language | English |
---|---|
Pages (from-to) | 38-41 |
Number of pages | 4 |
Journal | Multiple Sclerosis and Related Disorders |
Volume | 24 |
Early online date | 16 May 2018 |
DOIs | |
Publication status | Published - Aug 2018 |